• News
  • BioTech

Bristol-Myers Still Willing to Take Deal Bets Despite Two Misses

Jan. 15 (Bloomberg) -- Bristol-Myers Squibb Co. will continue to seek out innovative drugs to buy, particularly for cancer, shrugging off two previous deals totaling $7.8 billion in the last three years that failed to pay off for them.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!